Helicobacter pylori and nonsteroidal anti-inflammatory drugs. Approaching the end of the controversy in the new millennium or room for more debate?

Journal of Gastroenterology

Volumn 36, Issue 11, 2001, Pages 731-739

  Leong, R W L ^a   Chan, F K L ^a   Sung, J J Y ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Helicobacter pylori; Nonsteroidal anti inflammatory drug; Review

Indexed keywords

ACETYLSALICYLIC ACID; AMOXICILLIN; ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; BICARBONATE; BISMUTH; CELECOXIB; CLARITHROMYCIN; CORTICOSTEROID; CYTOKINE; DICLOFENAC; FAMOTIDINE; LANSOPRAZOLE; METRONIDAZOLE; MISOPROSTOL; NAPROXEN; NITRIC OXIDE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PLACEBO; PROSTAGLANDIN; PROSTAGLANDIN SYNTHASE; PROTON PUMP INHIBITOR; RANITIDINE; STOMACH SECRETION INHIBITOR; TETRACYCLINE;

ADAPTATION; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; CARDIOVASCULAR DISEASE; CHEMOTAXIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG USE; DUODENUM ULCER; DYSPEPSIA; GASTROINTESTINAL HEMORRHAGE; GRAM NEGATIVE INFECTION; HELICOBACTER PYLORI; HUMAN; HYDROPHOBICITY; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; STOMACH ACID; STOMACH BLOOD FLOW; STOMACH EROSION; STOMACH MUCOSA; STOMACH ULCER;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; PEPTIC ULCER;

EID: 0035210436     PISSN: 09441174     EISSN: None     Source Type: Journal    
DOI: 10.1007/s005350170014     Document Type: Review

References (69)

1. Working Party Report: Non-steroidal anti-inflammatory drug toxicity in the upper gastrointestinal tract
2. Quantitative study of apoptosis in normal rat gastroduodenal mucosa
3. Nonsteroidal anti-inflammatory drugs could reverse Helicobacter pylori-induced apoptosis and proliferation in gastric epithelial cells
4. Interaction of Helicobacter pylori eradication and non-steroidal anti-inflammatory drugs on gastric epithelial apoptosis and proliferation: Implications on ulcerogenesis
5. Expression and cellular localization of COX-1 and -2 in Helicobacter pylori gastritis
6. Localisation of cyclooxygenase 1 and cyclooxygenase 2 in Helicobacter pylori related gastritis and gastric ulcer tissues in humans
7. Up-regulation of cyclooxygenase-1 and -2 in human gastric ulcer
8. Interaction of NSAIDs and Helicobacter pylori on gastrointestinal injury and prostaglandin production: A controlled double-blind trial
9. Infection of Helicobacter pylori in gastric adaptation to continued administration of aspirin in man
10. Improved fold width and increased acid secretion after eradication of the organism in Helicobacter pylori associated enlarged fold gastritis
11. Helicobacter pylori infection may be a factor of suppressing the development of reflux esophagitis by inducing gastric hyposecretion
12. The urease enzymes of Campylobacter pylori and a related bacterium
13. Effect of age, Helicobacter pylori infection, and gastritis with atrophy on serum gastrin and gastric acid secretion in healthy men
14. Release of bicarbonate from damaged and restituted gastric mucosa in the cat
15. Influence of H. pylori infection on meal-stimulated gastric acid secretion and gastroesophageal acid reflux
16. Helicobacter pylori augments the pH-increasing effect of omeprazole in patients with duodenal ulcer
17. Helicobacter pylori infection potentiates the inhibition of gastric acid secretion by omeprazole
18. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal anti-inflammatory drugs
19. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal anti-inflammatory drugs
20. Nonsteroidal anti-inflammatory drug gastropathy
21. The mucoid cap over superficial gastric damage in the rat. A high-pH microenvironment dissipated by nonsteroidal antiinflammatory drugs and endothelin
22. Effect of acid and pepsin on blood coagulation and platelet aggregation. A possible contributor: Prolonged gastroduodenal mucosal hemorrhage
23. Influence of acid and angiogenesis on kinetics of gastric ulcer healing in rats: Interaction with indomethacin
24. Role of mucosal blood flow: A conceptional review in gastric mucosal injury and protection
25. Increased expression and cellular localization of inducible nitric oxide synthase and cyclooxygenase 2 in Helicobacter pylori gastritis
26. Helicobacter pylori induces apoptosis in gastric epithelial cells through inducible nitric oxide
27. Neutrophils, Helicobacter pylori, and non-steroidal anti-inflammatory drug ulcers
28. Nonsteroidal anti-inflammatory drugs inhibit Helicobacter pylori-induced human neutrophil reactive oxygen metabolite production in vitro
29. Effects of inflammatory cytokines induced by Helicobacter pylori infection on aminopyrine accumulation in parietal cells isolated from guinea pigs
30. Aspirin-induced gastritis, like Helicobacter pylori-induced gastritis disinhibits acid secretion in humans: Relation to cytokine expression
31. Effect of Helicobacter pylori products and recombinant cytokines on gastrin release from cultured canine G cells
32. Surface hydrophobicity of gastric mucosa in peptic ulcer disease-relationship to gastritis and Campylobacter pylori infection
33. Interaction of indomethacin and naproxen with gastric surface-active phospholipids: A possible mechanism for the gastric toxicity of nonsteroidal anti-inflammatory drugs
34. Helicobacter pylori-positive peptic ulcer patients do not adapt to aspirin
35. The influence of age, gender, Helicobacter pylori and smoking on gastric mucosal adaptation to nonsteroidal anti-inflammatory drugs
36. H. pylori infection increases the risk of non-steroidal anti-inflammatory drug (NSAID)-induced gastroduodenal ulceration
37. Peptic ulcer hemorrhage: Factors predisposing to recurrence
38. Peptic ulcer bleeding: Relative roles of Helicobacter pylori and non-steroidal anti-inflammatory drugs
39. Helicobacter pylori and risk of ulcer bleeding among users of nonsteroidal anti-inflammatory drugs: A case-control study
40. Interaction of risk factors for peptic ulcer bleeding
41. Helicobacter pylori infection is a protective factor for bleeding gastric ulcers but not for bleeding duodenal ulcers in NSAID users
42. Role of Helicobacter pylori infection on upper gastrointestinal bleeding in the elderly-a case-control study
43. Non-steroidal anti-inflammatory drugs, Helicobacter pylori and bleeding gastric ulcer
44. Influence of H. pylori infection and/or low-dose aspirin on gastroduodenal ulceration in patients treated with placebo, celecoxib, or NSAIDs
45. Helicobacter pylori: A risk and severity factor of non-steroidal anti-inflammatory drug induced gastropathy
46. The effect of Helicobacter pylori infection on NSAID-related gastroduodenal damage in the elderly
47. Campylobacter pylori associated gastritis in patients taking non-steroidal anti-inflammatory drugs
48. Serological evidence of infection with Helicobacter pylori may predict gastrointestinal intolerance to nonsteroidal anti-inflammatory drug (NSAID) treatment in rheumatoid arthritis
49. Prevalence of Helicobacter pylori infection and its effects on symptoms and nonsteroidal anti-inflammatory drug-induced gastrointestinal damage in patients with rheumatoid arthritis
50. Long-term non-steroidal antiinflammatory drug use and Helicobacter pylori infection
51. Long-term nonsteroidal anti-inflammatory drug use and gastrotroduodenal injury: The role of Helicobacter pylori
52. Nonsteroidal anti-inflammatory drug-induced dyspepsia-is Campylobacter pyloridis implicated?
53. Helicobacter pylori infection increases the risk of peptic ulcers in chronic users of non-steroidal anti-inflammatory drugs
54. Effect of Helicobacter pylori colonization on gastric mucosal eicosanoid synthesis in patients taking non-steroidal anti-inflammatory drugs
55. Effect of Helicobacter pylori infection on the severity of gastroduodenal mucosal injury after the acute administration of naproxen or aspirin to normal volunteers
56. Helicobacter pylori infection and the development of gastric or duodenal ulcer in arthritic patients receiving chronic NSAID therapy
57. Mucosal erosions in long term non-steroidal anti-inflammatory drug users: Predisposition to ulceration and relation to Helicobacter pylori
58. Superiority of lansoprazole vs ranitidine in healing nonsteroidal anti-inflammatory drug-associated gastric ulcers: Results of a double-blind, randomized, multicenter study
59. Prevention of peptic ulcer and dyspeptic symptoms with omeprazole in patients receiving continuous non-steroidal anti-inflammatory drug therapy
60. Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs
61. Primary gastroduodenal prophylaxis with omeprazole for non-steroidal anti-inflammatory drug users
62. Randomised trial of eradication of Helicobacter pylori before starting non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers
63. Does eradication of Helicobacter pylori before non-steroidal anti-inflammatory drug therapy reduce the long-term risk of ulcers? A double-blined randomised trial
64. Randomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs: HELP NSAIDs study
65. Does eradication of Helicobacter pylori impair healing of nonsteroidal anti-inflammatory drug associated bleeding peptic ulcers? A prospective randomized study
66. Role of Helicobacter pylori in ulcer healing and recurrence of gastric and duodenal ulcers in long term NSAID users: Response to omeprazole dual therapy
67. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or other nonsteroidal anti-inflammatory drugs
68. Double-blind trial of omeprazole and amoxycillin in the cure of Helicobacter pylori infection in gastric ulcer patients
69. Schistosomes, liver flukes and Helicobacter pylori